Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by research analysts at Mizuho from $205.00 to $250.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 102.74% from the stock’s previous close.

A number of other brokerages have also weighed in on PVLA. Oppenheimer reiterated an “outperform” rating and issued a $200.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th. BTIG Research boosted their price objective on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday. UBS Group reaffirmed a “buy” rating and issued a $143.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Finally, Canaccord Genuity Group increased their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $176.44.

Palvella Therapeutics Stock Up 2.4%

Shares of Palvella Therapeutics stock traded up $2.90 during trading on Wednesday, reaching $123.31. 202,786 shares of the stock were exchanged, compared to its average volume of 285,922. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -46.89 and a beta of -0.16. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $127.69. The stock’s fifty day moving average is $92.05 and its 200 day moving average is $78.51.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Hedge funds have recently bought and sold shares of the company. Group One Trading LLC boosted its stake in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the last quarter. Archer Investment Corp purchased a new position in Palvella Therapeutics during the third quarter valued at $28,000. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics during the third quarter valued at $36,000. China Universal Asset Management Co. Ltd. bought a new stake in Palvella Therapeutics during the fourth quarter valued at about $167,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Palvella Therapeutics in the second quarter worth about $37,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics News Summary

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Phase 3 SELVA topline: the trial met its primary endpoint (mean mLM-IGA +2.13, p<0.001), showed 95% of evaluable patients ≥6 improved and 86% “Much/Very Much Improved,” reported favorable safety (no drug‑related serious AEs) and plans an NDA submission in H2 2026 with potential U.S. approval in H1 2027 — a clear commercial catalyst if the FDA path proceeds. GlobeNewswire: SELVA Topline Results
• Positive Sentiment: Analyst upgrades/targets: BTIG raised its price target to $215 (buy) and Chardan to $210 (buy), signaling strong Street conviction and sizable upside vs. current levels — this adds buying pressure and institutional interest. Benzinga: BTIG Price Target The Fly: Chardan Price Target
• Neutral Sentiment: Market/technical coverage: multiple outlets note heavy momentum and the stock clearing its 50‑day moving average after the data — these pieces reflect trading dynamics rather than new fundamental information. MSN: Technical Momentum
• Negative Sentiment: Proposed public offering announced — expected to raise capital but introduces potential share dilution, which can offset enthusiasm from the trial news depending on deal size and timing. Business Insider: Proposed Public Offering
• Negative Sentiment: Insider activity shows multiple recent insider sales (7 sales, no purchases reported recently), which can weigh on sentiment even as fundamentals improve. Monitor size/timing of further insider moves. QuiverQuant: Phase 3 Results & Insider Data

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.